Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
26 November 2018 |
Main ID: |
EUCTR2012-001830-32-HU |
Date of registration:
|
16/08/2012 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A comparative study on the efficacy and tolerability of an 8 week oral treatment with three times daily 1000 mg mesalazine versus three times daily 2x500 mg mesalazine in patients with active ulcerative colitis
|
Scientific title:
|
Double-blind, double-dummy, randomised, multi-centre, comparative phase III clinical study on the efficacy and tolerability of an 8 week oral treatment with three times daily 1000 mg mesalazine versus three times daily 2x500 mg mesalazine in patients with active ulcerative colitis - TID 1000 mg mesalazine versus TID 2x500 mg mesalazine in active UC |
Date of first enrolment:
|
04/10/2012 |
Target sample size:
|
400 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-001830-32 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: yes Other trial design description: double-dummy If controlled, specify comparator, Other Medicinial Product: yes Placebo: no Other: no Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Hungary
|
Latvia
|
Lithuania
|
Poland
|
Russian Federation
|
Ukraine
| | |
Contacts
|
Name:
|
Project Manager
|
Address:
|
Leinenweberstr. 5
79108
Freiburg
Germany |
Telephone:
|
00497611514187 |
Email:
|
nacak@drfalkpharma.de |
Affiliation:
|
Dr. Falk Pharma GmbH |
|
Name:
|
Project Manager
|
Address:
|
Leinenweberstr. 5
79108
Freiburg
Germany |
Telephone:
|
00497611514187 |
Email:
|
nacak@drfalkpharma.de |
Affiliation:
|
Dr. Falk Pharma GmbH |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Signed informed consent, 2. Men or women aged 18 to 75 years, 3. Active ulcerative colitis, except proctitis limited to 15 cm ab ano, confirmed by endoscopy and histology, Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 300 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 100
Exclusion criteria: 1. Crohn's disease, indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis), 2. Toxic megacolon, 3. Screening stool positive for germs causing bowel disease, 4. Malabsorption syndromes, 5. Celiac disease, 6. Other inflammatory or bleeding disorders of the colon and intestine, or diseases that may cause diarrhoea or gastrointestinal bleeding,
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Active ulcerative colitis MedDRA version: 17.0
Level: LLT
Classification code 10045365
Term: Ulcerative colitis
System Organ Class: 100000004856
|
Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
|
Intervention(s)
|
Product Name: Mesalazine 1000 mg gastro-resistant tablets Product Code: Mesalazine 1000 mg gastro-resistant tablets Pharmaceutical Form: Gastro-resistant tablet INN or Proposed INN: Mesalazine CAS Number: 89-57-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3000- Pharmaceutical form of the placebo: Gastro-resistant tablet Route of administration of the placebo: Oral use
Trade Name: Salofalk® 500 mg gastro-resistant tablet Product Name: Mesalazine 500 mg gastro-resistant tablets (Salofalk® 500 mg) Product Code: Salofalk® 500 mg tablets Pharmaceutical Form: Gastro-resistant tablet INN or Proposed INN: Mesalazine CAS Number: 89-57-6 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 3000- Pharmaceutical form of the placebo: Gastro-resistant tablet Route of administration of the placebo: Oral use
|
Primary Outcome(s)
|
Secondary Objective: - To study safety and tolerability - To assess patients' acceptance and preference of trial drugs - To assess patients' quality of life
|
Primary end point(s): Rate of clinical remission after 8 weeks
|
Main Objective: The main objective of the trial is to proof the non-inferiority of an 8-week treatment with three times daily 1000mg mesalazine versus three times daily 2x500 mg mesalazine in patients with active ulcerative colitis
|
Timepoint(s) of evaluation of this end point: After 8 weeks of treatment
|
Secondary Outcome(s)
|
Secondary end point(s): Rate of clinical improvement (CAI) Number of stools per week Number of bloody stools per week Number of days with urgency per week Time to first resolution of clinical symptoms Patient’s Quality of Life Patient’s Global Satisfaction Patient’s acceptance and preference of trial drug Physician's Global Assessment Adverse Events (AEs) Vital signs (blood pressure, heart rate) and body weight Laboratory assessments
|
Timepoint(s) of evaluation of this end point: Each visit, if not otherwise defined
|
Secondary ID(s)
|
SAT-25/UCA
|
Source(s) of Monetary Support
|
Dr. Falk Pharma GmbH
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|